EANS-News: Epigenomics AG / Epigenomics AG to Provide an Update on the Septin9 Program During a Corporate Workshop on Colorectal Cancer Screening at the Association of Molecular Pathology (AMP) 2012 A

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A. (euro adhoc) - Press release

Epigenomics AG to Provide an Update on the Septin9 Program During a
Corporate Workshop on Colorectal Cancer Screening at the Association
of Molecular Pathology (AMP) 2012 Annual Meeting

* Partners Quest Diagnostics and ARUP Laboratories to discuss
experiences with laboratory developed test versions using the
methylated Septin9 DNA biomarker

Berlin, Germany, and Seattle, WA, U.S.A., October 22, 2012 -
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular
diagnostics company, today announced that it will host a corporate
workshop at the Association of Molecular Pathology (AMP) 2012 Annual
Meeting. Attendees of AMP, analysts, investors and media
representatives are cordially invited to join this event on October
24, 2012 at 4pm PST in room 102 at the Long Beach Convention &
Entertainment Center in Long Beach, CA.

The workshop will include a presentation of the results from the
pivotal trial with Epigenomics' colorectal cancer blood test, Epi
proColon®, for US pre-market approval, as well as discussions on the
individual experiences and perspectives of various groups using the
Septin9 biomarker. Presentations will be made by:

* Nicholas Potter, Ph.D., FACMG, Chief Scientific Officer and
Director of Molecular Diagnostics at Molecular Pathology Laboratory
Network, Inc., Maryville, TN

"Septin9 in the Molecular Diagnostics Setting: Results of the
Epigenomics Pivotal Trial"

* Frederic Waldman, MD Ph.D., Medical Director, Cancer Diagnostics,
Quest Diagnostics Nichols Institute, San Juan Capistrano CA

"ColoVantage®, Methylated Septin9: Quest Diagnostics' Experience with
its Laboratory-Developed Blood Test for the Colorectal Cancer Genetic
Marker After Tens of Thousands of Tests Performed"

* Karen Heichman, Ph.D., Adjunct Associate Professor of Pathology at
the University of Utah School of Medicine and VP Oncology Technology
Development and Licensing of ARUP Laboratories, Inc., Salt Lake City,
UT

"ARUP's Experience with the SEPT9 Blood-based Colorectal Cancer Test"

* Professor Dr. Béla Molnár, MD Ph.D., Department of Internal
Medicine of Semmelweis University in Budapest, Hungary

"Update on Septin9 Research"

Karen Heichman, Ph.D., Adjunct Associate Professor of Pathology at
the University of Utah School of Medicine and VP Oncology Technology
Development and Licensing of ARUP said: "ARUP continues to see steady
volumes of our Septin9 colorectal cancer test. Based on our
collaborative research demonstrating strong patient preference for
blood-based testing, it is clear that as physicians and patients
become informed, molecular tests such as Septin9 will play an
increasing role in patient care."

"We are extremely pleased to have this year's lineup of speakers and
contributors at our workshop," said Noel Doheny, CEO of Epigenomics'
US Subsidiary. "AMP represents an important opportunity to inform the
medical community of the work that we and our partners are doing
using Septin9 testing."

Dr. Thomas Taapken, CEO/CFO of Epigenomics AG remarked that
"Epigenomics is highly anticipating the results of its Septin9
biomarker-based test, Epi proColon®, compared directly to the fecal
immunochemical test (FIT). The results of the comparison study will
be included in the pre-market application for the use of Epi
proColon® as a colorectal cancer screening test to be submitted to
FDA later this year."

The workshop is designed to update the AMP laboratory community about
the growing opportunity for laboratories to help improve
participation in colorectal cancer testing. The increasing
availability of blood-based molecular diagnostic method allows
patients more flexible choices for their routine health care. The
addition of these types of assays provides an innovative role for
molecular laboratories and builds on their historic molecular testing
expertise.

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English